BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 26385822)

  • 1. Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients.
    De Rose F; Cozzi L; Navarria P; Ascolese AM; Clerici E; Infante M; Alloisio M; Testori A; Toschi L; Finocchiaro G; Santoro A; Scorsetti M
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):13-20. PubMed ID: 26385822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
    Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
    Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments.
    Navarria P; Ascolese AM; Tomatis S; Cozzi L; De Rose F; Mancosu P; Alongi F; Clerici E; Lobefalo F; Tozzi A; Reggiori G; Fogliata A; Scorsetti M
    Radiat Oncol; 2014 Apr; 9(1):91. PubMed ID: 24694067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.
    Li Q; Swanick CW; Allen PK; Gomez DR; Welsh JW; Liao Z; Balter PA; Chang JY
    Radiother Oncol; 2014 Aug; 112(2):256-61. PubMed ID: 25108807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
    Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy for central lung tumors.
    Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
    J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.
    Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
    J Thorac Oncol; 2011 Dec; 6(12):2036-43. PubMed ID: 21892102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
    Tekatli H; van 't Hof S; Nossent EJ; Dahele M; Verbakel WFAR; Slotman BJ; Senan S
    J Thorac Oncol; 2017 Jun; 12(6):974-982. PubMed ID: 28286243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
    Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer.
    Bongers EM; Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
    J Thorac Oncol; 2011 Dec; 6(12):2052-7. PubMed ID: 22052227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
    McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies.
    Mesko S; Sandler K; Cohen J; Konecny G; Steinberg M; Kamrava M
    Int J Gynecol Cancer; 2017 Feb; 27(2):403-408. PubMed ID: 27870704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
    Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
    Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription.
    Mihai AM; Armstrong PJ; Hickey D; Milano MT; Dunne M; Healy K; Thirion P; Heron DE; ElBeltagi N; Armstrong JG
    Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):627-637. PubMed ID: 34092462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.